Home  |  Contact

UniProtKB/Swiss-Prot O14773: Variant p.Ala448Val

Tripeptidyl-peptidase 1
Gene: TPP1
Variant information

Variant position:  448
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Type of variant:  LP/P [Disclaimer]
The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance

Residue change:  From Alanine (A) to Valine (V) at position 448 (A448V, p.Ala448Val).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.

Physico-chemical properties:  Change from small size and hydrophobic (A) to medium size and hydrophobic (V)
The physico-chemical property of the reference and variant residues and the change implicated.

BLOSUM score:  0
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Variant description:  In CLN2.
Any additional useful information about the variant.



Sequence information

Variant position:  448
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Protein sequence length:  563
The length of the canonical sequence.

Location on the sequence:   KFLSSSPHLPPSSYFNASGR  A YPDVAALSDGYWVVSNRVPI
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.

Residue conservation: 
The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         KFLSSSPHLPPSS---YF--NASGRAYPDVAALSDGYWVVSNRVPI

                              QFLSSSPHLPPSS---YF--NASGRAYPDVAALSDGYWVVS

Chimpanzee                    KFLSSSPHLPPSS---YF--NASGRAYPDVAALSDGYWVVS

Mouse                         QFLKSSSHLPPSS---YF--NASGRAYPDVAALSDGYWVVS

Rat                           QFLKSSSHLPPSS---YF--NASGRAYPDVAALSDGYWVVS

Bovine                        RYLSSSPHLPPSS---YF--NASGRAYPDVAALSDGYWVVS

Zebrafish                     AYLKSVQSLPPQT---YF--NTTGRAYPDLAALSDNYWVVS

Slime mold                    SYIEWLNG-SLSS---FY--NQSGRGFPDISSFSENVVILY

Baker's yeast                 ----------------YYCGDAAGRK----KDFSDSDIKFA

Fission yeast                 NWMDDIKGLGLSAEHGSFVRKPHSTTWINLAELLDMSWKKE

Sequence annotation in neighborhood:  
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.

TypePositionsDescription
Chain 196 – 563 Tripeptidyl-peptidase 1
Domain 199 – 563 Peptidase S53
Glycosylation 443 – 443 N-linked (GlcNAc...) asparagine
Disulfide bond 365 – 526
Beta strand 446 – 449


Literature citations

Update of the mutation spectrum and clinical correlations of over 360 mutations in eight genes that underlie the neuronal ceroid lipofuscinoses.
Kousi M.; Lehesjoki A.E.; Mole S.E.;
Hum. Mutat. 33:42-63(2012)
Cited for: VARIANTS CLN2 THR-62; HIS-209; GLN-266; GLN-339; ARG-382; VAL-448; CYS-501; TYR-504 AND ARG-548;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.